tetano
Editor, Senior Moderator
Intern Med
. 2022 Mar 26.
doi: 10.2169/internalmedicine.9209-21. Online ahead of print.
Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan
Takayuki Fujii[SUP] 1 2 [/SUP], Masao Hagihara[SUP] 1 [/SUP], Keiko Mitamura[SUP] 3 [/SUP], Shiori Nakashima[SUP] 1 [/SUP], Shin Ohara[SUP] 1 [/SUP], Tomoyuki Uchida[SUP] 1 [/SUP], Morihiro Inoue[SUP] 1 [/SUP], Moe Okuda[SUP] 4 [/SUP], Atsuhiro Yasuhara[SUP] 4 [/SUP], Jurika Murakami[SUP] 4 [/SUP], Calvin Duong[SUP] 4 [/SUP], Kiyoko Iwatsuki-Horimoto[SUP] 4 [/SUP], Seiya Yamayoshi[SUP] 4 5 [/SUP], Yoshihiro Kawaoka[SUP] 4 5 [/SUP]
Affiliations
Abstract
Objective Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. Methods In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. Results In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). Conclusion Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group.
Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 IgG antibodies.
. 2022 Mar 26.
doi: 10.2169/internalmedicine.9209-21. Online ahead of print.
Anti-SARS CoV-2 IgG in COVID-19 Patients with Hematological Diseases: A Single-center, Retrospective Study in Japan
Takayuki Fujii[SUP] 1 2 [/SUP], Masao Hagihara[SUP] 1 [/SUP], Keiko Mitamura[SUP] 3 [/SUP], Shiori Nakashima[SUP] 1 [/SUP], Shin Ohara[SUP] 1 [/SUP], Tomoyuki Uchida[SUP] 1 [/SUP], Morihiro Inoue[SUP] 1 [/SUP], Moe Okuda[SUP] 4 [/SUP], Atsuhiro Yasuhara[SUP] 4 [/SUP], Jurika Murakami[SUP] 4 [/SUP], Calvin Duong[SUP] 4 [/SUP], Kiyoko Iwatsuki-Horimoto[SUP] 4 [/SUP], Seiya Yamayoshi[SUP] 4 5 [/SUP], Yoshihiro Kawaoka[SUP] 4 5 [/SUP]
Affiliations
- PMID: 35342138
- DOI: 10.2169/internalmedicine.9209-21
Abstract
Objective Coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Although the relationship between anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies and COVID-19 severity has been reported, information is lacking regarding the seropositivity of patients with particular types of diseases, including hematological diseases. Methods In this single-center, retrospective study, we compared SARS-CoV-2 IgG positivity between patients with hematological diseases and those with non-hematological diseases. Results In total, 77 adult COVID-19 patients were enrolled. Of these, 30 had hematological disorders, and 47 had non-hematological disorders. The IgG antibody against the receptor-binding domain of the spike protein was detected less frequently in patients with hematological diseases (60.0%) than in those with non-hematological diseases (91.5%; p=0.029). Rituximab use was significantly associated with seronegativity (p=0.010). Conclusion Patients with hematological diseases are less likely to develop anti-SARS-CoV-2 antibodies than those with non-hematological diseases, which may explain the poor outcomes of COVID-19 patients in this high-risk group.
Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 IgG antibodies.